Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

@article{Lewis2001RenoprotectiveEO,
  title={Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.},
  author={E J Lewis and Lawrence G. Hunsicker and W R Clarke and Tom{\'a}s Berl and Marc A. Pohl and J B Lewis and E Ritz and Robert C. Atkins and R Rohde and I Raz},
  journal={The New England journal of medicine},
  year={2001},
  volume={345 12},
  pages={851-60}
}
BACKGROUND It is unknown whether either the angiotensin-II-receptor blocker irbesartan or the calcium-channel blocker amlodipine slows the progression of nephropathy in patients with type 2 diabetes independently of its capacity to lower the systemic blood pressure. METHODS We randomly assigned 1715 hypertensive patients with nephropathy due to type 2 diabetes to treatment with irbesartan (300 mg daily), amlodipine (10 mg daily), or placebo. The target blood pressure was 135/85 mm Hg or less… CONTINUE READING
Highly Influential
This paper has highly influenced 92 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Recent Discussions
This paper has been referenced on Twitter 11 times over the past 90 days. VIEW TWEETS